StockData
GRAIL, Inc. logo

GRAIL, Inc. (GRAL) stock

GRALNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/30
$105.88+0.28 (+0.27%)

Close on Nov 17, 2026Market cap $4.73BP/E –Yield –

Grail r&d expenses

Research and development expenses are spending on new products and technology.

Grail's R&D Expenses for the twelve months ending Jun 30, 2026 was $190.99M, down 15.8% year over year. For fiscal 2025 it was $195.79M, down 39.3% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$195.79M-39.3%
FY2024Dec 31, 2024$322.38M-4.8%
FY2023Dec 31, 2023$338.75M+2.8%
FY2022Jan 1, 2023$329.58M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$47.43M+1.7%
Q1 FY2026Mar 31, 2026$48.02M-10.5%
Q4 FY2025Dec 31, 2025$46.90M-3.0%
Q3 FY2025Sep 30, 2025$48.65M-37.8%
Q2 FY2025Jun 30, 2025$46.63M-50.5%
Q1 FY2025Mar 31, 2025$53.63M-47.2%
Q4 FY2024Dec 31, 2024$48.33M–
Q3 FY2024Sep 30, 2024$78.23M–
Q2 FY2024Jun 30, 2024$94.20M–
Q1 FY2024Mar 31, 2024$101.63M–

More Grail figures

See a number that looks wrong?